Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$278.00K$278.00KN/M vs Q2 2023 Net Income-$6.59M-$6.59MN/M vs Q2 2023 EPS Diluted-$0.66-$0.66no prior Q2 2023 on file Operating Income-$6,780,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-2438.8%
Net margin-2369.8%
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end